▲ Peaking
Health
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
Novartis reports that its IL-6 inhibitor, Pacibekitug, achieved sustained reductions in inflammation biomarkers over six months in the TRANQUILITY trial.